Retatrutide Research Guide

Full name: Retatrutide (Triple Agonist GIP/GLP-1/Glucagon)

A novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 shows unprecedented 24% body weight loss at 48 weeks.

How Retatrutide Works

Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity.

Dosing Protocol

• Typical dose: 1-2 mg → titrate up to 12 mg
• Frequency: Once weekly
• Duration: Ongoing (investigational)
• Route: Subcutaneous injection

Reported Benefits

• Unprecedented weight loss (~24%)
• Significant liver fat reduction
• Improved cardiovascular markers
• Enhanced energy expenditure
• Superior glycemic control

Potential Side Effects

• GI effects (nausea, diarrhea, vomiting)
• Decreased appetite
• Heart rate increase

Research Citations

1. Phase 2 trial of retatrutide for obesity (2023) - At 48 weeks, retatrutide 12mg achieved 24.2% mean weight loss with 26% losing 30%+ body weight.
2. Retatrutide effects on hepatic steatosis (2023) - Reduced liver fat by 81-86% with complete resolution of steatosis in up to 90% of participants.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile
• Survodutide - Full Profile

View full Retatrutide profile with 3D molecule viewer →